Recorded as renamed to Knoa Pharmaceutical Products LLC (2026)
10 patents currently held
23 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Jan 2027. from the record
Of the 23 now held by other companies, 8 name Knoa Pharma LLC as their current owner, and 15 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
2
Ending by 2030
Jan 2027
Next term end
7
Patent families
When these terms end
Held patents by the year their term ends
notable patents
all others
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Oct 2036 · High confidence
Also notable
Ends May 2035 · High confidence
Also notable
Ends Jan 2030 · High confidence
Also notable
Ends Sep 2034 · High confidence
Also notable
Ends Sep 2032 · High confidence
Also notable
Ends Mar 2033 · High confidence
Also notable
Ends Jan 2027 · High confidence
Hodgkin Lymphoma Therapy
US 11,266,631
Cited by 22 later US patents, top 5% of utility patents granted in 2022 in our data. Protection runs to 2036.
Combination Comprising a Glucocorticoid and EDO-S101
US 11,541,038
Cited by 21 later US patents, top 5% of utility patents granted in 2023 in our data. Protection runs to 2035. A terminal disclaimer caps this term to an earlier patent's.
Hydroxamic Acid Derivatives
US 9,096,627
Cited by 28 later US patents, top 25% of utility patents granted in 2015 in our data, and renewed at every maintenance window due so far. Protection runs to 2030.
Novel Therapeutic Agents
US 10,118,901
The most cited patent in this portfolio, cited by 52 later US patents, top 5% of utility patents granted in 2018 in our data. Protection runs to 2034.
Nitrogen Mustard Derivatives
US 8,962,855
Cited by 39 later US patents, top 25% of utility patents granted in 2015 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2032.
Pharmaceutical Compositions
US 9,376,395
Cited by 28 later US patents, top 25% of utility patents granted in 2016 in our data, and renewed at every maintenance window due so far. Protection runs to 2033.
Methods of Treating Opiate Dependency and Preventing Non-Oral Opiate Abuse Among Opiate Addicts
US 10,507,205
Granted 2019. Computed term ends 2027.
Formerly held, still cited
Notable
Ends May 2035 · High confidence
Cited by 21 later US patents, top 5% of utility patents granted in 2023 in our data. Protection runs to 2035. A terminal disclaimer caps this term to an earlier patent's.
now held by Knoa Pharma LLC
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Feb 4, 2027The maintenance fee for Hydroxamic Acid Derivatives (US 9,096,627) comes due Feb 4, 2027. Unpaid by Aug 4, 2027, it lapses early.
- 1 fee due Mar 26, 2027The maintenance fee for Hodgkin Lymphoma Therapy (US 11,766,424) comes due Mar 26, 2027. Unpaid by Sep 27, 2027, it lapses early.
Recent changes
- Sep 29Assignment recorded on US RE46,144: Purdue Pharmaceutical Products L.P. to Knoa Pharmaceutical Products LLC Recorded Sep 29, 2026, executed May 1, 2026. Conveyance as recorded: Change of Name. A recorded assignment is a filed document, not a statement of current ownership. Reel 76585, frame 720.
What they patent
The largest of its 7 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Hodgkin Lymphoma Therapy | 3 in force | to Oct 2036 |
| Combination Comprising a Glucocorticoid and EDO-S101 | 2 in force | to May 2035 |
| Novel Therapeutic Agents | 1 in force | to Sep 2034 |
| Pharmaceutical Compositions | 1 in force | to Mar 2033 |
| Nitrogen Mustard Derivatives | 1 in force | to Sep 2032 |
| Hydroxamic Acid Derivatives | 1 in force | to Jan 2030 |
| Methods of Treating Opiate Dependency and Preventing Non-Oral Opiate Abuse Among Opiate Addicts | 1 in force | to Jan 2027 |
Patents held now
Soonest term end first.
Showing 1 to 10 of 10
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,507,205 | Methods of Treating Opiate Dependency and Preventing Non-Oral Opiate Abuse Among Opiate Addicts In force · High confidence | In force | High confidence | |
| US 9,096,627 | Hydroxamic Acid Derivatives In force · High confidence | In force | High confidence | |
| US 8,962,855 | Nitrogen Mustard Derivatives In force · High confidence | In force | High confidence | |
| US 9,376,395 | Pharmaceutical Compositions In force · High confidence | In force | High confidence | |
| US 10,118,901 | Novel Therapeutic Agents In force · High confidence | In force | High confidence | |
| US 10,744,120 | Combination Comprising a Glucocorticoid and EDO-S101 In force · High confidence | In force | High confidence | |
| US 11,541,038 | Combination Comprising a Glucocorticoid and EDO-S101 In force · High confidence | In force | High confidence | |
| US 11,266,631 | Hodgkin Lymphoma Therapy In force · High confidence | In force | High confidence | |
| US 11,766,424 | Hodgkin Lymphoma Therapy In force · High confidence | In force | High confidence | |
| US 12,440,475 | Hodgkin Lymphoma Therapy In force · High confidence | In force | High confidence |
Also on record, not counted in the 10: 23 patents in force now held by others · 21 patents ended · 8 applications pending · 12 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.